We used the subcutaneously administered B16 melanoma model of tumor immunity, which is widely used to study anti-tumor immune responses The B16-OVA cell line has been engineered to express the ovalbumin protein (OVA) in the context of MHC Class I, which allows analysis of SIINFEKL-specific CD8+ T cell responses as a proxy for an endogenous tumor associated antigen (20). Here, CD8A is linked to melanoma.